文献速递冠心病血脂与心血管预防

冠状动脉内结构-分子成像OCT-FLIm多靶点表征高危斑块的首人体研究

Intracoronary Structural-Molecular Imaging for Multitargeted Characterization of High-Risk Plaque: First-in-Human OCT-FLIm.
PubMed 文献 · JAMA Cardiol · 2025-01-01

这项前瞻性单中心诊断可行性研究纳入40例需血运重建的显著冠心病患者,首次人体验证OCT-FLIm双模态成像的临床可行性与安全性。结果显示OCT提供斑块结构特征,FLIm可重复地表征斑块分子组成,急性冠脉综合征患者斑块炎症FL值显著高于慢性稳定型心绞痛患者,快速进展病变的愈合斑块FL值显著高于非进展对照。

要点

  • OCT-FLIm可安全、可重复地同时获取冠脉斑块结构与分子信息。
  • 急性冠脉综合征患者斑块炎症FL值显著高于慢性稳定型心绞痛患者。
  • 快速进展病变的愈合斑块FL值显著高于非进展对照病变。

核心结论

  • OCT-FLIm结构-分子冠脉内成像在人体中临床可行且安全,可全面表征动脉粥样硬化斑块。
  • 该技术有望用于高危斑块的诊断与生物学理解。

研究设计与样本

  • 前瞻性、开放标签、单中心诊断可行性研究,纳入40例需冠脉血运重建的显著冠心病患者。
  • 2022年2月至8月开展首人体OCT-FLIm成像,2022年8月至2023年7月进行分析。
  • 使用2.6-F导管的OCT-FLIm系统,对所有患者靶/罪犯及非靶/非罪犯病变成像,并行血管内超声对比。

主要发现

  • OCT提供斑块结构特征,FLIm可重复表征斑块分子特征,包括巨噬细胞、愈合斑块、浅表钙化和纤维化。
  • 斑块成分的荧光寿命值与既往尸检研究结果相关。
  • 急性冠脉综合征患者炎症FL均值(SD)为7.59(0.96)纳秒,慢性稳定型心绞痛患者为6.46(0.87)纳秒(P < .001)。
  • 快速进展病变的愈合斑块FL均值(SD)为5.31(0.20)纳秒,非进展对照病变为4.81(0.30)纳秒(P < .001)。
  • 所有患者安全接受OCT-FLIm,无不良临床事件。

关键数值与推荐

  • 主要结局为评估FLIm衍生的预设斑块成分分子读数。
  • 次要结局为OCT-FLIm在不同动脉粥样硬化疾病活动亚组(ACS vs CSA;造影快速进展 vs 非进展对照)中确定靶/罪犯斑块成分的可行性。

临床怎么用

  • OCT-FLIm可作为冠脉内结构-分子联合成像工具,辅助识别高危斑块。
  • FLIm分子读数可用于区分斑块炎症活跃程度及愈合斑块表型。
  • 该技术安全性良好,支持进一步临床验证。

局限性

  • 单中心、开放标签、样本量40例的诊断可行性研究。
  • 首人体研究,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fluorescence lifetime imaging (FLIm) is a molecular imaging technique used to visualize the biochemical composition of atherosclerosis. Novel dual-modal imaging using optical coherence tomography (OCT)-FLIm has the potential to provide both microstructural and biocompositional information on coronary plaques; however, it needs validation for clinical application. OBJECTIVE: To investigate the clinical feasibility and safety of OCT-FLIm for characterizing plaque compositions in patients with coronary artery disease (CAD) undergoing revascularization therapy. DESIGN, SETTING, AND PARTICIPANTS: A prospective, open-label, single-center diagnostic feasibility study involving 40 patients with significant CAD requiring coronary revascularization. This first-in-human clinical study of the novel intracoronary OCT-FLIm imaging was conducted between February and August 2022. The analyses were performed from August 2022 to July 2023. INTERVENTIONS: An OCT-FLIm system with 2.6-F catheters was constructed. All patients underwent OCT-FLIm for target/culprit and nontarget/nonculprit lesions during coronary revascularization. Intravascular ultrasound imaging was performed for comparison. MAIN OUTCOMES AND MEASURES: The primary outcome was to assess the FLIm-derived molecular readouts of prespecified plaque compositions. The secondary outcome was the feasibility of OCT-FLIm in determining target/culprit plaque compositions across different subsets of atherosclerotic disease activity: (1) acute coronary syndrome (ACS) vs chronic stable angina (CSA) and (2) angiographic rapid disease progression vs nonprogressive controls. RESULTS: We prospectively enrolled 40 patients (mean [SD] age, 63.1 [8.1] years; 32 men [80.0%]), of whom 20 presented with ACS and 20 with CSA. OCT provided the structural features of plaques, and FLIm characterized the molecular signatures of atheroma compositions, including macrophages, healed plaques, superficial calcification, and fibrosis, in a reproducible manner. Fluorescence lifetime (FL) values of the plaque compositions correlated with findings from prior autopsy studies. Plaque inflammation was significantly greater in patients with ACS than those with CSA. The mean (SD) of inflammation-FL was 7.59 (0.96) nanoseconds for patients with ACS vs 6.46 (0.87) nanoseconds for patients with CSA (P < .001). The healed plaque phenotype was more prominently distributed in the segments of rapid disease progression than in nonprogressive controls. The mean (SD) healed plaque-FL was 5.31 (0.20) nanoseconds for the rapidly progressive lesions vs 4.81 (0.30) nanoseconds for the rapidly nonprogressive lesions (P < .001). All patients underwent OCT-FLIm safely without adverse clinical events. CONCLUSIONS AND RELEVANCE: This diagnostic feasibility study found that an OCT-FLIm structural-molecular intracoronary imaging is clinically feasible and safe for the comprehensive characterization of human atheromas, supporting its potential role in the diagnosis and biological understanding of high-risk plaques.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kim S, Nam HS, Kang DO, et al. Intracoronary Structural-Molecular Imaging for Multitargeted Characterization of High-Risk Plaque: First-in-Human OCT-FLIm. JAMA Cardiol. 2025. PMID: 40332864. doi:10.1001/jamacardio.2025.0928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。